CL2017001913A1 - Composición tópica curativa - Google Patents

Composición tópica curativa

Info

Publication number
CL2017001913A1
CL2017001913A1 CL2017001913A CL2017001913A CL2017001913A1 CL 2017001913 A1 CL2017001913 A1 CL 2017001913A1 CL 2017001913 A CL2017001913 A CL 2017001913A CL 2017001913 A CL2017001913 A CL 2017001913A CL 2017001913 A1 CL2017001913 A1 CL 2017001913A1
Authority
CL
Chile
Prior art keywords
results
herpes
faster
dosage
curing
Prior art date
Application number
CL2017001913A
Other languages
English (en)
Inventor
Melwyn Abreo
Carol Mcbride
Talal Sheena
Original Assignee
Florengale Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florengale Llc filed Critical Florengale Llc
Publication of CL2017001913A1 publication Critical patent/CL2017001913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p> </p> <p>SE PROPORCIONAN, ENTRE OTRAS, COMPOSICIONES ESTABILIZADAS NUEVAS PARA TRATAR AFECCIONES CUTÁNEAS EN DONDE SE APLICA UNA DOSIFICACIÓN TERAPÉUTICAMENTE EFICAZ DE UN COMPUESTO DE AZUFRE QUE RESULTA EN LA CURACIÓN. LA DOSIFICACIÓN UTILIZADA DE COMPUESTO DE AZUFRE RESULTA EN UNA DESCOMPOSICIÓN MÁS RÁPIDA DE LA ESTRUCTURA DE LA CÁPSIDE DEL VIRUS Y RESULTAR, POR EJEMPLO, EN UNA CURACIÓN MÁS RÁPIDA. EL RÉGIMEN DE DOSIFICACIÓN PARA MANTENER LAS CONCENTRACIONES DEL AMINOÁCIDO QUE CONTIENE AZUFRE EN EL SITIO AFECTADO TAMBIÉN AYUDA A LOGRAR UNA CURACIÓN MÁS RÁPIDA. LAS FORMULACIONES Y LOS MÉTODOS SE PUEDEN APLICAR A UNA VARIEDAD DE AFECCIONES CUTÁNEAS QUE INCLUYEN HERPES LABIAL, HERPES, HERPES GENITAL Y CULEBRILLA.</p>
CL2017001913A 2015-01-27 2017-07-26 Composición tópica curativa CL2017001913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562108492P 2015-01-27 2015-01-27

Publications (1)

Publication Number Publication Date
CL2017001913A1 true CL2017001913A1 (es) 2018-04-27

Family

ID=56544280

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001913A CL2017001913A1 (es) 2015-01-27 2017-07-26 Composición tópica curativa

Country Status (9)

Country Link
US (2) US10682324B2 (es)
EP (1) EP3250196A4 (es)
JP (1) JP2018503689A (es)
AU (1) AU2016211605A1 (es)
CA (1) CA2974011A1 (es)
CL (1) CL2017001913A1 (es)
HK (1) HK1247827A1 (es)
PE (1) PE20180026A1 (es)
WO (1) WO2016123223A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10293012B2 (en) 2017-05-04 2019-05-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods of using extracts of melissa officinalis against filoviruses
WO2018208739A1 (en) * 2017-05-08 2018-11-15 Thomas Cahill Pharmaceutical compositions comprising caffeic acid chelates
US11166982B2 (en) 2018-10-03 2021-11-09 Harold H. Simeroth Multi-type stem cell activation with nano silver
ES2759400A1 (es) * 2018-11-07 2020-05-08 Consejo Superior Investigacion INHIBIDORES DE TGF-ß1 Y PRODUCTORES DE ENDOGLINA PARA SU USO EN EL TRATAMIENTO DE EPIDERMOLISIS BULLOSA
JP7373794B2 (ja) * 2019-11-15 2023-11-06 デンカ株式会社 没食子酸又は没食子酸結合化合物を含有する液剤
CN113051713B (zh) * 2021-03-01 2023-03-21 东方电气集团科学技术研究院有限公司 基于图像灰度共生矩阵多特征提取的复合材料老化预测方法
WO2024050405A1 (en) * 2022-08-30 2024-03-07 Green Shawn J Compositions and methods for improving nitric oxide levels in intraoral, nasal and/or nasopharyngeal area
CN117982468A (zh) * 2023-12-29 2024-05-07 武汉市第三医院 一种erk激动剂促进糖尿病足创面愈合应用及药物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2527757B2 (ja) * 1987-07-17 1996-08-28 リ−・ロイ・モ−ガン 皮膚の炎症を減少させる化合物およびその組成物
DE3822096A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Stabilisierte arzneimittelzubereitung
TW222591B (es) 1991-08-30 1994-04-21 Procter & Gamble
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5691380A (en) * 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
IN2000KO00299A (es) 1999-05-28 2005-11-18 Johnson & Johnson Consumer
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US7374772B2 (en) 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
EP1877044A4 (en) * 2005-04-21 2009-09-02 Glenn A Goldstein AMIDE N-ACETYLCYSTEINE (AMIDE NAC) FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH OXIDATIVE STRESS
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP4954531B2 (ja) * 2005-10-31 2012-06-20 一丸ファルコス株式会社 ペルオキシソーム増殖剤応答性受容体活性化剤
WO2007070562A2 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Non-hygroscopic compositions of enterostatin
EP1959930A2 (en) * 2005-12-14 2008-08-27 Zars, Inc. Flux-enabling compositions and methods for dermal delivery of drugs
EA016043B1 (ru) * 2006-07-25 2012-01-30 Замбон С.П.А Косметические или дерматологические препараты, содержащие n-ацетилцистеин
WO2009031318A1 (ja) * 2007-09-05 2009-03-12 Kowa Co., Ltd. 鎮痛・抗炎症剤含有外用剤
GB2470040A (en) 2009-05-06 2010-11-10 Systagenix Wound Man Ip Co Bv Wound dressing material comprising N-acetyl cysteine
CN105687177A (zh) * 2009-07-15 2016-06-22 小利兰·斯坦福大学托管委员会 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
EP2397125A1 (en) * 2010-06-15 2011-12-21 Histocell, S.L. Antioxidant composition
WO2013138744A1 (en) * 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
CL2014003326A1 (es) 2014-12-05 2015-03-20 Univ Chile Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.

Also Published As

Publication number Publication date
CA2974011A1 (en) 2016-08-04
JP2018503689A (ja) 2018-02-08
US20210015777A1 (en) 2021-01-21
EP3250196A1 (en) 2017-12-06
HK1247827A1 (zh) 2018-10-05
EP3250196A4 (en) 2018-09-26
PE20180026A1 (es) 2018-01-09
WO2016123223A1 (en) 2016-08-04
US10682324B2 (en) 2020-06-16
US20180015060A1 (en) 2018-01-18
AU2016211605A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CL2017001913A1 (es) Composición tópica curativa
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2020001743A2 (es) Métodos de tratamiento para la fibrosis quística
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO6710926A2 (es) Compuestos de n-heteroarilo
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
NI201200196A (es) Agentes terapéuticos 976
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа